We came across one bullish thesis at Syndax Pharmaceuticals, Inc. in the BioEquity Watch substack. In this article, we will summarize the bulls’ thesis on SNDX. The stock of Syndax Pharmaceuticals, Inc. it was trading at $20.67 on January 15.

Phovoir/Shutterstock.com

Syndax Pharmaceuticals has become a commercial-stage biotech anchored by two first-in-class approved therapies, Revuforj (revumenib) and Niktimvo (axatilimab), each addressing areas of high unmet medical need. Revuforj is an oral menin inhibitor approved for relapsed or refractory acute leukemias with KMT2A rearrangements, where disruption of the Menin-KMT2A interaction shuts down oncogenic gene expression and causes leukemic cell differentiation and death.

Based on this approval, Syndax is pursuing expansion into NPM1 mutant AML through a supplemental NDA supported by the AUGMENT-101 data, while advancing first-line combination studies that could significantly expand its addressable market. Niktimvo, an anti-CSF-1R monoclonal antibody approved for heavily pretreated chronic graft-versus-host disease, targets macrophage-mediated inflammation and fibrosis, offering a distinct mechanism over existing therapies. Its pipeline expansion in IPF and combination regimens in cGVHD further expands its long-term potential.

Financially, Syndax is well capitalized, with approximately $518 million in cash and investments as of Q2 2025. Revuforj is showing strong early commercial traction, generating quarterly net revenue of $28.6 million with sequential growth, while Incyte’s collaboration revenue supports the launch of Niktimvo. While the company remains loss-making due to high R&D and commercial spending, management expects existing cash and growing revenue to fund operations through profitability.

Strategically, Syndax benefits from first-mover advantage in menin inhibition, exposure to genetically defined leukemia populations with limited competition, and revenue diversification across oncology and immune-mediated diseases. With late-2025 regulatory catalysts, expanding clinical programs and growing commercial adoption, Syndax presents a compelling long-term growth opportunity driven by the execution of its two core assets.

Previously, we covered a bullish thesis at Sarepta Therapeutics, Inc. (SRPT) by Magnus Ofstad in January 2025, which highlighted the company’s leadership in Duchenne muscular dystrophy, accelerating revenues and the attractiveness of the acquisition. SRPT’s share price has depreciated approximately 81.94% since our coverage due to safety concerns and regulatory uncertainty surrounding Elevidys. BioEquity Watch shares a similar view, but emphasizes the commercial execution and world-class hematology assets at Syndax Pharmaceuticals.